“Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects” by Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger. Nat Commun 13, 873 (2022). https://doi.org/10.1038/s41467-022-28410-9

“Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors” by Adam C. Palmer, Benjamin Izar , Haeun Hwangbo and Peter K. Sorger. Clin Cancer Res (2022) 28 (2): 368–377. https://doi.org/10.1158/1078-0432.CCR-21-2275